Jaroslaw Leszczyszyn

Appearances

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Date
May 7, 2023
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Presenter
Bruce Sands
Speakers
Laurent Peyrin-Biroulet
Silvio Danese
David T. Rubin
University of Chicago Division of the Biological Sciences
Severine Vermeire
Christopher Ma
Timothy Ritter
Remo Panaccione
Brian Feagan
Western University
Dermot P.B. Mcgovern
Cedars-Sinai Medical Center
Olivier Laurent
Allison Luo
Deanna Nguyen
JD Lu
Anna Wiechowska-Kozlowska
Jaroslaw Leszczyszyn
Radoslaw Kempinski
Jaroslaw Kierkus
Stephan Targan